HMC launches advanced neuro modulation services for mental health patients at Mesaieed General Hospital

Doha, Qatar: Hamad Medical Corporation (HMC) proudly announces the launch of two innovative treatment options for patients with treatment resistant de...

Doha, Qatar: Hamad Medical Corporation (HMC) proudly announces the launch of two innovative treatment options for patients with treatment-resistant depression at its Mental Health Service at Mesaieed General Hospital: Esketamine and Transcranial Magnetic Stimulation (TMS).

Dr. Ovais Wadoo FRCP(Edin), FRCPsych, Senior Consultant and Clinical Lead for Neuromodulation Services at HMC, states, “The introduction of Esketamine marks a crucial advancement in our approach to treating depression. This nasal spray offers hope to patients who have struggled with traditional treatments, providing them with a new avenue for recovery.”

Esketamine is FDA-approved and administered in a clinical setting under the supervision of healthcare professionals. This treatment is particularly beneficial for individuals who have not responded to other antidepressants.

In addition to Esketamine, HMC will soon offer TMS therapy, which utilizes magnetic pulses to stimulate specific brain regions associated with mood regulation. Dr. Ovais explains, “TMS is a non-invasive alternative for patients who either cannot tolerate the side effects of traditional medications or have found them ineffective. We are pleased to offer this service to our patients.”